MGMT and central nervous system cancer: Administration of the BAC regimen for patients with primary grade 3 gliomas was beneficial for those with IDH-wild-type and MGMT-methylated gliomas in terms of OS (Figure 3, Supplementary Figure S4) and for those with MGMT-methylated gliomas in terms of both OS and PRS (Supplementary Figure S3).